Accessibility Menu
ENvue Medical logo

ENvue Medical(NASDAQ) NAOV

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year-96%
1 Month-38%
N/A
ENvue Medical last closing stock price
MetricPriceDate
Last closeUSD 0.362026-07-27
ENvue Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.15%USD 0.372026-07-20
1 month-37.89%USD 0.582026-06-26
3 month-71.38%USD 1.252026-04-28
Year to date-84.51%USD 2.312025-12-31
1 year-96.03%USD 9.012025-07-25
3 year-99.9%USD 353.102023-07-28
5 year-99.99%USD 4,202.002021-07-28
Since inception-100%USD 7,700.002015-05-28

ENvue Medical Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.18M

Net Income (TTM)

-$19.51M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 18, 2026

NAOV News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ENvue Medical

NanoVibronix makes medical devices for pain relief and wound care at home. Its products help people manage pain, heal wounds, and prevent infections without hospital visits. The company’s devices use ultrasound technology to support daily health needs for patients and caregivers.

Gadgets That Heal: Products and Services

  • UroShield: Ultrasound device for urinary catheter users to reduce infection and discomfort.
  • PainShield: Patch-based ultrasound for pain relief, muscle spasms, and joint stiffness, used at home.
  • WoundShield: Patch-based ultrasound device to help wounds heal and support tissue repair.
  • ENvue segment (10% of H1 2025 revenue): Devices for enteral feeding, helping patients receive nutrition through feeding tubes.

Plot Twists: Growth and Expansion

  • Acquired ENvue Medical Holdings in February 2025, entering the enteral feeding device market.
  • Expanded product line with PainShield MD Plus, though FDA clearance was withdrawn in August 2025.
  • Raised net proceeds of $8.2 million in May 2025 and gross proceeds of $8 million in July 2025 through preferred stock offerings.
  • Launched clinical trial with University of Michigan in 2025 to support product claims.
  • Operates in the U.S. Israel, Europe, India, and other international markets through direct sales and distributors.

Why NanoVibronix Stands Out

The company focuses on non-invasive, home-use medical devices, making care more accessible. Its global distribution network covers the U.S. Europe, and beyond. Proprietary ultrasound technology and a mix of direct and distributor sales support its market presence.

Five Things You Need to Know

  • Q2 2025 revenue was $494,000, down 39.5% from Q2 2024.
  • Gross margin turned negative in Q2 2025, at –7% versus +52% in Q2 2024.
  • Net loss for Q2 2025 was approximately $3.97 million, up 477% from Q2 2024.
  • Cash balance was approximately $4.06 million as of June 30, 2025, after equity raises.
  • Largest distributor accounted for only 2% of Q2 2025 revenue, down from 52% a year earlier.

Bottom Line

NanoVibronix has diversified through acquisitions and expanded its product range. The company faces financial challenges but continues to adapt its business model and product offerings.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

14

CEO

Doron Robert Besser, MD

Website

www.nanovibronix.com

Headquarters

Elmsford, NY 10523, US

NAOV Financials

Key Financial Metrics (TTM)

Gross Margin

-12.43%

Operating Margin

-623.29%

Net Income Margin

-744.15%

Return on Equity

-43.73%

Return on Capital

-68.09%

Return on Assets

-40.71%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$271.00K

Operating Income

-$24.75M

EBITDA

$3.52M

Operating Cash Flow

-$12.34M

Capital Expenditure

-$72.00K

Free Cash Flow

-$12.41M

Cash & ST Invst.

$2.24M

Total Debt

$130.00K

ENvue Medical Performance Analysis

ENvue Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 752,000-55.6%
20232023-12-31USD 2,283,000203.6%
20242024-12-31USD 2,558,00012.0%
20252025-12-31USD 2,553,000-0.2%
ENvue Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-51.8%
Q32025-09-3046.2%
Q42025-12-31-56.8%
Q12026-03-31109.3%
ENvue Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -422.14-66.2%
20232023-12-31USD -233.25-44.7%
20242024-12-31USD -137.30-41.1%
20252025-12-31USD -26.69-80.6%
ENvue Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3074.1%
Q32025-09-30-8.7%
Q42025-12-31-1935.7%
Q12026-03-3194.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$653.00K

-36.3%

Gross Profit

-$55.00K

-114.9%

Gross Margin

-8.42%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

31

N/A

Net Income

-$3.82M

-53.2%

EBITDA

$217.00K

+109.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.24M

+271.9%

Total Debt

$130.00K

-96.7%

Accounts Receivable

$1.33M

+7.7%

Inventory

$2.27M

+12.2%

Long Term Debt

$35.00K

+105.9%

Short Term Debt

$95.00K

-97.6%

Return on Assets

-40.71%

N/A

Return on Invested Capital

-41.19%

N/A

Free Cash Flow

-$4.33M

-221.1%

Operating Cash Flow

-$4.31M

-221.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BJDXBluejay Diagnostics, Inc.
$1.10+6.80%
VEROVenus Concept Inc.
$0.31+2.64%
BBLGBone Biologics Corporation
$1.03-4.21%
MOVECorvex, Inc.
$12.64+1.12%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About NAOV

What is the current price of ENvue Medical?

ENvue Medical is trading at N/A per share.

What is the 52-week range for ENvue Medical?

Over the past 52 weeks, ENvue Medical has traded between N/A and N/A.

How much debt does ENvue Medical have?

As of the most recent reporting period, ENvue Medical reported total debt of $1.21M.

How much cash does ENvue Medical have on hand?

ENvue Medical reported $2.27M in cash and cash equivalents in its most recent financial results.

What is ENvue Medical’s dividend yield?

ENvue Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services